Samsung Bioepis Executives Weigh US Biosimilar Progress
For The US Biosimilars Market, ‘Pace Of Progress Has To Improve To Ensure Future Viability’
Executive Summary
In an exclusive Q&A interview with Generics Bulletin, Samsung Bioepis executives Tom Newcomer and Gillian Woollett discuss the progress made by US biosimilars so far, the developments that are expected in the months and years to come, as well as the action that is needed to ensure a viable biosimilars market going forward.